文献速递自身炎症与 IgG4 相关病

IgG4相关疾病的临床结局与医疗资源利用:美国商业保险成人索赔数据分析

The clinical outcomes and healthcare resource utilization in IgG4-related disease: a claims-based analysis of commercially insured adults in the United States.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

该队列研究基于美国管理式医疗组织索赔数据,纳入524例IgG4相关疾病(IgG4-RD) Incident病例和5240例按年龄、性别、种族/民族及索引日期匹配的普通人群对照,评估索引日期前12个月及后36个月内21项专家定义的临床结局及医疗就诊与费用。大多数病例在索引日期前(64.0%)和后(85.1%)接受糖皮质激素治疗;几乎所有结局在病例组中更常见,胃食管反流病、感染、高血压和糖尿病的患病率差异最大,随访期间病例组住院和急诊就诊更频繁且所有费用更高。

要点

  • 病例组索引日期前接受糖皮质激素者占64.0%,索引日期后占85.1%。
  • 随访期间病例组与对照组患病率差异最大者为胃食管反流病(+31.2%,P < 0.001)、感染(+17.3%,P < 0.001)、高血压(+15.5%,P < 0.01)和糖尿病(+15.0%,P < 0.001)。
  • 随访期间病例组住院(57.3% vs 17.2%,P < 0.01)和急诊就诊(72.0% vs 36.7%,P < 0.01)更频繁,所有费用均高于对照组。

核心结论

  • IgG4-RD患者不成比例地受到不良结局影响,其中部分可能通过临床医生警惕监测而预防或改善;减少糖皮质激素的治疗可能改善这些结局。

研究设计与样本

  • 使用美国管理式医疗组织索赔数据的队列研究,采用经验证的算法识别新发IgG4-RD病例,普通人群对照按年龄、性别、种族/民族和索引日期匹配。

主要发现

  • 共纳入524例病例和5240例对照,大多数病例在索引日期前(64.0%)和后(85.1%)接受糖皮质激素治疗。
  • 随访期间病例组与对照组患病率差异最大者为胃食管反流病(+31.2%,P < 0.001)、感染(+17.3%,P < 0.001)、高血压(+15.5%,P < 0.01)和糖尿病(+15.0%,P < 0.001)。
  • 随访期间恶性肿瘤差异从+8.8%增至+12.5%(P < 0.001)。
  • 17.4%的病例在随访期间使用胰腺酶替代治疗。
  • 随访期间病例组更常住院(57.3% vs 17.2%,P < 0.01)和/或急诊就诊(72.0% vs 36.7%,P < 0.01),所有费用均高于对照组。

临床怎么用

  • 原文结论认为,部分不良结局可能通过临床医生警惕监测而预防或改善,减少糖皮质激素的治疗可能改善这些结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: IgG4-related disease (IgG4-RD) can affect nearly any organ and is often treated with glucocorticoids, which contribute to organ damage and toxicity. Comorbidities and healthcare utilization in IgG4-RD are poorly understood. METHODS: We conducted a cohort study using claims data from a US managed care organization. Incident IgG4-RD cases were identified using a validated algorithm; general population comparators were matched by age, sex, race/ethnicity and index date. The frequency of 21 expert-defined clinical outcomes associated with IgG4-RD or its treatment and healthcare-associated visits and costs were assessed 12 months before and 36 months after the index date (date of earliest IgG4-RD-related claim). RESULTS: There were 524 cases and 5240 comparators. Most cases received glucocorticoids prior to (64.0%) and after (85.1%) the index date. Nearly all outcomes, many being common glucocorticoid toxicities, occurred more frequently in cases vs comparators. During follow-up, the largest differences between cases and comparators were seen for gastroesophageal reflux disease (prevalence difference: +31.2%, P < 0.001), infections (+17.3%, P < 0.001), hypertension (+15.5%, P < 0.01) and diabetes mellitus (+15.0%, P < 0.001). The difference in malignancy increased during follow-up from +8.8% to +12.5% (P < 0.001). Some 17.4% of cases used pancreatic enzyme replacement therapy during follow-up. Over follow-up, cases were more often hospitalized (57.3% vs 17.2%, P < 0.01) and/or had an emergency room visit (72.0% vs 36.7%, P < 0.01); all costs were greater in cases than comparators. CONCLUSIONS: Patients with IgG4-RD are disproportionately affected by adverse outcomes, some of which may be preventable or modifiable with vigilant clinician monitoring. Glucocorticoid-sparing treatments may improve these outcomes.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Wallace ZS, Miles G, Smolkina E, et al. The clinical outcomes and healthcare resource utilization in IgG4-related disease: a claims-based analysis of commercially insured adults in the United States. Rheumatology (Oxford). 2024. PMID: 38637947. doi:10.1093/rheumatology/keae230

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。